ATLANTA, Oct. 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that: (i) DexCom had made material design changes to the G6 and G7 unauthorized by the United States Food and Drug Administration (the "FDA"); (ii) the foregoing design changes rendered the ...